MP48: Prostate Cancer: Advanced (including Drug Therapy) III

Sunday, May 15, 2022

2:45 PM – 4:00 PM

Location: Room 225

Poster Session Moderator(s)

Todd Morgan, MD

Jack Lapides, MD, Research Professor
University of Michigan
Brian Chapin, MD, FACS

The University of Texas, M.D. Anderson Cancer Center
Chengfei Liu, MD, PHD

Assistant Professor
University of California, Davis

Presentations:

2:45 PM – 4:00 PM

MP48-01: How to optimize patient selection before salvage lymph node dissection for nodal recurrent prostate cancer: a novel risk stratification tool
Poster Presenter: Nicola Fossati
2:45 PM – 4:00 PM

MP48-02: Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Localized Prostate Cancer
Poster Presenter: Jessica Delgado, MD,MS
2:45 PM – 4:00 PM

MP48-03: Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis
Poster Presenter: Amanda E. Hird, MD
2:45 PM – 4:00 PM

MP48-04: Evaluating Cardiovascular Risk in Men Starting Androgen Deprivation Therapy for Prostate Cancer
Poster Presenter: Benjamin Hugh Lowentritt, MD – Chesapeake Urology Associates. P.A
2:45 PM – 4:00 PM

MP48-05: Changes in pituitary–gonadal hormones after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): results from a randomised clinical trial
Poster Presenter: Klara Kvorning Ternov, MD – Herlev and Gentofte Hospital
2:45 PM – 4:00 PM

MP48-06: Adverse events related to Darolutamide treatment: analysis of “real life” data from EudraVigilance (EV) and the Food and Drug Administration (FDA) database entries
Poster Presenter: Antonio Cicione
2:45 PM – 4:00 PM

MP48-07: The neurotoxicity of androgen deprivation therapy: a pharmacovigilance study
Poster Presenter: Logan Briggs, BA
2:45 PM – 4:00 PM

MP48-08: Response Rates and Survival Outcomes of Metastasis Directed Therapies in Solitary Oligo-recurrent Prostate Cancer
Poster Presenter: Mohamed El Sayed Hassan Ahmed, MD
2:45 PM – 4:00 PM

MP48-09: Toxicity profile of immediate post-prostatectomy radiation therapy: results from a large multi-institutional series
Poster Presenter: Nicola Fossati
2:45 PM – 4:00 PM

MP48-10: Androgen Deprivation Therapy for Node-Positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: Contemporary Practice Patterns and Associated Factors
Poster Presenter: Raju Chelluri
2:45 PM – 4:00 PM

MP48-11: Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance database
Poster Presenter: Antonio Nacchia
2:45 PM – 4:00 PM

MP48-12: Optimizing Timing And Indications For 68Ga-PSMA PET/CT In Patients With Biochemical Recurrent Prostate Cancer After Radical Prostatectomy
Poster Presenter: Daniele Robesti
2:45 PM – 4:00 PM

MP48-13: The Key Role Of Concomitant Androgen-Deprivation Therapy On The Efficacy Of Imaging Guided Treatments In Men With Biochemical Recurrent Prostate Cancer After Radical Prostatectomy And Positive 68Ga-PSMA PET/CT Scan
Poster Presenter: Daniele Robesti
2:45 PM – 4:00 PM

MP48-14: When Node-Positive Prostate Cancer Should Be Considered A Systemic Disease? Assessing The Prognostic Role Of Preoperative 68Ga-PSMA PET/CT Results In Patients With Lymph Node Invasion At Final Pathology
Poster Presenter: Daniele Robesti
2:45 PM – 4:00 PM

MP48-15: Correlation Between¹⁸F-DCFPyL PET Detected Local Recurrence and Radical Prostatectomy Histopathology: A Pilot Study.
2:45 PM – 4:00 PM

MP48-16: ¹⁸F-DCFPyL PSMA PET Imaging Improves Detection of Nodal Metastases in Comparison to Conventional Imaging in Patients with Locally Advanced or Oligometastatic Prostate Cancer
Poster Presenter: Ashanda Esdaille, MD
2:45 PM – 4:00 PM

MP48-17: Oncological outcomes in patients with recurrent prostate cancer staged with PSMA PET/CT: results from 3 European tertiary centers
Poster Presenter: Lorenzo Bianchi, MD – Alma Mater Studiorum, University of Bologna, Department of Urology Bologna
2:45 PM – 4:00 PM

MP48-18: The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort
Poster Presenter: Mariaconsiglia Ferriero, MD, PHD – "Regina Elena" National Cancer Institute
2:45 PM – 4:00 PM

MP48-19: Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer
Poster Presenter: Lillian Y. Lai, MD,MS
2:45 PM – 4:00 PM

MP48-20: Protective Effects of Metformin against Biochemical Failure Following Radical Prostatectomy or Radiation Therapy in Localized Prostate Cancer
Poster Presenter: Linda My Huynh, MS